KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Total Liabilities: 2010-2024

Historic Total Liabilities for Pacira BioSciences (PCRX) over the last 15 years, with Dec 2024 value amounting to $775.2 million.

  • Pacira BioSciences' Total Liabilities fell 26.13% to $570.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $570.4 million, marking a year-over-year decrease of 26.13%. This contributed to the annual value of $775.2 million for FY2024, which is 10.07% up from last year.
  • According to the latest figures from FY2024, Pacira BioSciences' Total Liabilities is $775.2 million, which was up 10.07% from $704.3 million recorded in FY2023.
  • In the past 5 years, Pacira BioSciences' Total Liabilities ranged from a high of $1.3 billion in FY2021 and a low of $654.8 million during FY2020.
  • For the 3-year period, Pacira BioSciences' Total Liabilities averaged around $795.2 million, with its median value being $775.2 million (2024).
  • As far as peak fluctuations go, Pacira BioSciences' Total Liabilities spiked by 105.39% in 2021, and later slumped by 32.62% in 2022.
  • Pacira BioSciences' Total Liabilities (Yearly) stood at $654.8 million in 2020, then skyrocketed by 105.39% to $1.3 billion in 2021, then tumbled by 32.62% to $906.2 million in 2022, then decreased by 22.28% to $704.3 million in 2023, then climbed by 10.07% to $775.2 million in 2024.